Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3453-3456

  Ly, Neang S ^a   Yang, Jenny ^a   Bulitta, Jurgen B ^a,b   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CONTROLLED STUDY; NONHUMAN; PHOP GENE; PHOQ GENE; PMRA GENE; PMRB GENE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REGULATORY MECHANISM; TWO COMPONENT REGULATORY SYSTEM;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLISTIN; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; TRANSCRIPTION FACTORS;

EID: 84861108467     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06380-11     Document Type: Article

References (31)

1. Adams MD, et al. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634.
2. Brown MR, Melling J. 1969. Role of divalent cations in the action of polymyxin B and EDTA on Pseudomonas aeruginosa. J. Gen. Microbiol. 59:263-274.
3. CLSI. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Denton M, et al. 2002. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr. Pulmonol. 34:257-261.
5. Fernandez L, et al. 2010. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob. Agents Chemother. 54:3372-3382.
6. Garonzik SM, et al. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294.
7. Gunn JS, et al. 1998. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol. Microbiol. 27:1171-1182. (Pubitemid 28137969)
8. Gunn JS, Miller SI. 1996. PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. J. Bacteriol. 178:6857-6864. (Pubitemid 26404962)
9. Harigaya Y, et al. 2009. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob. Agents Chemother. 53:3894-3901.
10. Henry R, et al. 2012. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-acetylglucosamine. Antimicrob. Agents Chemother. 56:59-69.
11. Kallel H, et al. 2006. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int. J. Antimicrob. Agents 28:366-369. (Pubitemid 44403003)
12. Kayama S, et al. 2009. The role of rpoS gene and quorum-sensing system in ofloxacin tolerance in Pseudomonas aeruginosa. FEMS Microbiol. Lett. 298:184-192.
13. Kwon DH, Lu CD. 2006. Polyamines induce resistance to cationic peptide, aminoglycoside, and quinolone antibiotics in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 50:1615-1622.
14. Lee JY, Song JH, Ko KS. 2011. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea. Microb. Drug Resist. 17:299-304.
15. Li J, et al. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992. (Pubitemid 38008420)
16. Li J, et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
17. Li J, et al. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950. (Pubitemid 44396396)
18. Macfarlane EL, Kwasnicka A, Hancock RE. 2000. Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 146(Part 10):2543-2554.
19. Matthaiou DK, et al. 2008. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit. Care Med. 36:807-811.
20. McPhee JB, Lewenza S, Hancock RE. 2003. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 50:205-217. (Pubitemid 37222798)
21. Miller AK, et al. 2011. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 55:5761-5769.
22. Moskowitz SM, et al. 2012. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 56:1019-1030.
23. Moskowitz SM, et al. 2004. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 186:575-579. (Pubitemid 38076447)
24. Muhle SA, Tam JP. 2001. Design of Gram-negative selective antimicrobial peptides. Biochemistry 40:5777-5785. (Pubitemid 32440882)
25. Schuster M, Greenberg EP. 2006. A network of networks: quorum-sensing gene regulation in Pseudomonas aeruginosa. Int. J. Med. Microbiol. 296:73-81. (Pubitemid 43375989)
26. Soncini FC, Groisman EA. 1996. Two-component regulatory systems can interact to process multiple environmental signals. J. Bacteriol. 178:6796-6801. (Pubitemid 26404954)
27. Stover CK, et al. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964.
28. Trent MS, Ribeiro AA, Lin S, Cotter RJ, Raetz CR. 2001. An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L- arabinose to lipid A: induction on polymyxin-resistant mutants and role of a novel lipid-linked donor. J. Biol. Chem. 276:43122-43131.
29. Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF. 2008. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob. Agents Chemother. 52:1533-1537. (Pubitemid 351522028)
30. Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. 2000. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44: 3317-3321. (Pubitemid 33014325)
31. Zhang Q, et al. 2011. Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science 333:1764-1767.